sacituzumab govitecan
Showing 1 - 25 of 59
Lung Cancer Trial (Sacituzumab Govitecan, Pembrolizumab)
Not yet recruiting
- Lung Cancer
- Sacituzumab Govitecan
- Pembrolizumab
- (no location specified)
Sep 20, 2023
Esophagogastric Adenocarcinoma Trial (Sacituzumab govitecan)
Not yet recruiting
- Esophagogastric Adenocarcinoma
- Sacituzumab govitecan
- (no location specified)
Nov 9, 2023
Triple Negative Breast Cancer Trial (Sacituzumab govitecan, Pembrolizumab)
Not yet recruiting
- Triple Negative Breast Cancer
- Sacituzumab govitecan
- Pembrolizumab
- (no location specified)
Oct 5, 2023
Gland, Salivary Gland Cancers Trial in Houston (Sacituzumab Govitecan)
Not yet recruiting
- Gland
- Salivary Gland Cancers
- Sacituzumab Govitecan
-
Houston, TexasM D Anderson Cancer Center
May 22, 2023
Ovarian Cancer, Malignant Tumor of Uterus Trial in New York (Sacituzumab, Cisplatin)
Not yet recruiting
- Ovarian Cancer
- Malignant Neoplasm of Uterus
-
New York, New YorkIcahn School of Medicine at Mount Sinai Division of Hematology a
Sep 14, 2023
Cervical Cancer Trial (Sacituzumab Govitecan)
Not yet recruiting
- Cervical Cancer
- Sacituzumab Govitecan
- (no location specified)
Apr 18, 2023
Ovarian Carcinoma Trial in New Haven (Sacituzumab govitecan)
Not yet recruiting
- Ovarian Carcinoma
- Sacituzumab govitecan
-
New Haven, ConnecticutSmilow Cancer Hospital at Yale New Haven
Aug 31, 2023
Gastrointestinal Cancer Trial (Capecitabine, Sacituzumab govetican)
Not yet recruiting
- Gastrointestinal Cancer
- Capecitabine
- Sacituzumab govetican
- (no location specified)
Oct 2, 2023
Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic Trial in Boston (Sacituzumab Govitecan,
Not yet recruiting
- Her 2 Positive Breast Cancer
- +2 more
- Sacituzumab Govitecan
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 25, 2023
Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 Trial in Seattle
Recruiting
- Muscle Invasive Bladder Carcinoma
- +2 more
- Lymphadenectomy
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 9, 2023
Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma Trial in Cleveland (Sacituzumab
Not yet recruiting
- Localized Muscle Invasive Bladder Urothelial Carcinoma
- Muscle-Invasive Bladder Carcinoma
- Sacituzumab govitecan
- Adaptive Radiotherapy
-
Cleveland, OhioCleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Apr 18, 2023
Breast Cancer Trial in Boston (Talazoparib, Sacituzumab Govitecan)
Recruiting
- Breast Cancer
- Talazoparib
- Sacituzumab Govitecan
-
Boston, Massachusetts
- +1 more
Jan 6, 2023
Metastatic Urothelial Carcinoma Trial in Tampa, Boston (Ipilimumab, Nivolumab, Sacituzumab govitecan)
Recruiting
- Metastatic Urothelial Carcinoma
- Ipilimumab
- +2 more
-
Tampa, FloridaMoffitt Cancer Center
Jan 24, 2023
Breast Cancer Trial in Houston (Sacituzumab Govitecan, Pembrolizumab)
Not yet recruiting
- Breast Cancer
- Sacituzumab Govitecan
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Dec 22, 2022
Urothelial Bladder Carcinoma Trial in Spain (Sacituzumab govitecan, Zimberelimab, Domvanalimab)
Not yet recruiting
- Urothelial Bladder Carcinoma
- Sacituzumab govitecan
- +2 more
-
Santiago De Compostela, A Coruña, Spain
- +9 more
Nov 14, 2023
HRD Cancer, SCLC, Advanced Solid Tumors Trial run by the NCI (Berzosertib, Sacituzumab Govitecan)
Recruiting
- HRD Cancer
- +2 more
- Berzosertib
- Sacituzumab Govitecan
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter Trial in
Recruiting
- Urothelial Cancer
- +3 more
- Sacituzumab Govitecan (SG)
- Enfortumab vedotin-ejfv (EV)
-
Boston, MassachusettsDana Farber Cancer Institute
Sep 28, 2022
Advanced or Metastatic Solid Tumor, Liver Failure Trial in United States (Sacituzumab Govitecan-hziy)
Recruiting
- Advanced or Metastatic Solid Tumor
- Liver Failure
- Sacituzumab Govitecan-hziy
-
Long Beach, California
- +5 more
Jan 6, 2023
Muscle-invasive Urothelial Carcinoma of the Bladder Trial in Milan (Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA])
Not yet recruiting
- Muscle-invasive Urothelial Carcinoma of the Bladder
- Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]
-
Milan, MI, ItalyFondazione San Raffaele
Sep 8, 2022
Triple Negative Breast Cancer, Metastatic Breast Cancer Trial (Sacituzumab govitecan)
Not yet recruiting
- Triple Negative Breast Cancer
- Metastatic Breast Cancer
- Sacituzumab govitecan
- (no location specified)
Jan 23, 2023
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab
Recruiting
- Locally Advanced or Unresectable Metastatic Breast Cancer
- Stage IV Breast Cancer
- Sacituzumab Govitecan-hziy
- +3 more
-
Marietta, Georgia
- +1 more
Apr 21, 2023
Metastatic Triple Negative Breast Cancer Trial (Sabizabulin, Sacituzumab Govitecan-hziy, Sabizabulin/Sacituzumab govitecan-hziy
Withdrawn
- Metastatic Triple Negative Breast Cancer
- Sabizabulin
- +2 more
- (no location specified)
Jan 24, 2022
Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer Trial in United States (Pembrolizumab, Sacituzumab
Recruiting
- Invasive Breast Cancer
- +3 more
- Pembrolizumab
- Sacituzumab Govitecan
-
Atlanta, Georgia
- +7 more
Nov 14, 2022
Endometrial Carcinoma Trial in New Haven (Sacituzumab Govitecan)
Recruiting
- Endometrial Carcinoma
- Sacituzumab Govitecan
-
New Haven, ConnecticutSmilow Cancer Hospital at Yale New Haven
Apr 4, 2022
NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Sacituzumab Govitecan
- Pembrolizumab
-
Marietta, Georgia
- +2 more
Jan 27, 2023